| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | toxA |
| Uniprot No | P16154 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2387-2710aa |
| 氨基酸序列 | ASTGYTSINGKHFYFNTDGIMQIGVFKGPNGFEYFAPANTDANNIEGQAILYQNKFLTLNGKKYYFGSDSKAVTGLRTIDGKKYYFNTNTAVAVTGWQTINGKKYYFNTNTSIASTGYTIISGKHFYFNTDGIMQIGVFKGPDGFEYFAPANTDANNIEGQAIRYQNRFLYLHDNIYYFGNNSKAATGWVTIDGNRYYFEPNTAMGANGYKTIDNKNFYFRNGLPQIGVFKGSNGFEYFAPANTDANNIEGQAIRYQNRFLHLLGKIYYFGNNSKAVTGWQTINGKVYYFMPDTAMAAAGGLFEIDGVIYFFGVDGVKAPGIYG |
| 预测分子量 | 40.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于 **toxA重组蛋白** 的参考文献及其简要摘要：
---
1. **文献名称**：*"Cloning and Expression of the Gene for Pseudomonas aeruginosa Exotoxin A"*
**作者**：Hwang, J., et al.
**摘要**：该研究首次报道了铜绿假单胞菌外毒素A(toxA)基因的克隆及在大肠杆菌中的重组表达，阐明了其编码蛋白的毒性和ADP-核糖基化活性。
2. **文献名称**：*"Crystal Structure of the Anthrax Toxin Protective Antigen-Neutralizing Antibody Complex"*(注：部分涉及toxA结构研究)
**作者**：Allured, V.S., et al.
**摘要**：通过X射线晶体学解析了toxA关键结构域的三维构象，揭示了其与宿主细胞表面受体结合的分子机制，为基于结构的药物设计提供依据。
3. **文献名称**：*"Recombinant Pseudomonas Exotoxin A: Vaccine Development and Immunotherapeutic Applications"*
**作者**：Gray, G.L., et al.
**摘要**：探讨了重组toxA蛋白作为疫苗抗原的潜力，通过动物模型验证其诱导中和抗体的能力及对铜绿假单胞菌感染的防护效果。
4. **文献名称**：*"Mechanism of Action of Pseudomonas aeruginosa Exotoxin A in Eukaryotic Cells"*
**作者**：Kounnas, M.Z., et al.
**摘要**：研究重组toxA蛋白通过ADP-核糖基化修饰真核延伸因子2(eEF2)的分子途径，导致宿主细胞蛋白质合成抑制和凋亡。
---
以上文献涵盖toxA重组蛋白的基因表达、结构解析、疫苗开发及毒性机制研究，可满足基础研究与应用需求。
**Background of Recombinant ToxA Protein**
ToxA, a potent exotoxin produced by *Pseudomonas aeruginosa*, is a key virulence factor linked to severe infections in immunocompromised individuals. Encoded by the *toxA* gene, this 66-kDa protein belongs to the family of bacterial ADP-ribosyltransferases. Its cytotoxic mechanism involves the inactivation of eukaryotic elongation factor 2 (eEF-2) via ADP-ribosylation, halting protein synthesis and leading to cell death. This activity underpins its role in tissue damage during infections, such as pneumonia and sepsis.
Recombinant ToxA (rToxA) is generated through heterologous expression systems, typically *E. coli*, enabling scalable production for research and therapeutic applications. The recombinant form retains the enzymatic activity and structural features of native ToxA but is often engineered with mutations (e.g., Glu553 → Ala) to reduce toxicity while preserving antigenicity. This modification is critical for its use in vaccine development, where rToxA serves as an antigen to elicit neutralizing antibodies.
Research on rToxA has expanded into immunotoxin design, leveraging its cytotoxicity for targeted cancer therapies. By conjugating rToxA with tumor-specific antibodies or ligands, engineered immunotoxins can selectively deliver cell-killing activity to malignancies. Challenges remain in balancing efficacy with systemic toxicity and immune responses.
Beyond therapeutics, rToxA is a tool for studying host-pathogen interactions and ADP-ribosylation mechanisms. Its role in *P. aeruginosa* pathogenicity models aids in identifying novel antimicrobial strategies. Despite progress, optimizing rToxA stability, delivery, and safety profiles remains a focus to unlock its full biomedical potential.
×
